# Gilead Sciences, Inc.  Share Price Target ‘$75.50’, now 13.4% Upside Potential

- Link: https://www.directorstalkinterviews.com/gilead-sciences-inc.share-price-target-75.50-now-13.4-upside-potential/4121163977
- Published: 2024-07-05T16:01:42+01:00
- Author: Charlotte Edwards

**Gilead Sciences, Inc.** with ticker code (GILD) have now 25 confirmed analysts
covering the stock with the consensus suggesting a rating of ‘buy’. The range between
the high target price and low target price is between $110.25 and $62.08 with the
average share target price sitting at $75.50. (at the time of writing). Given that
the stocks previous close was at $66.59 and the analysts are correct then we can
expect a percentage increase in value of 13.4%. Also worth taking note is the 50
day moving average now sits at $66.14 and the 200 day moving average is $73.77. 
The company has a market capitalization of 82.33B. The stock price for the company
is currently $66.08 USD

 The potential market cap would be $93,341,272,622 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 183.56, revenue per share of $22.00
and a 10.5% return on assets.

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in 
advancing medicines to prevent and treat life-threatening diseases, including human
immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products
in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy,
Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir)
is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus
disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus
and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV)(
Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (
HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products
include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors
targeting PARP1 for oncology and MK2 for inflammatory diseases.

Share on: